SCHEMBL6516737

SCHEMBL6516737

CCn1c(=O)c2ccsc2n(C)c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 5/20 0.44
ADORA2A P29274 4/20 0.42
PDE4B Q07343 3/20 0.42
PDE4A P27815 2/20 0.42
PDE4C Q08493 2/20 0.42
PDE4D Q08499 2/20 0.42
ERCC1 P07992 1/20 0.41
ERCC5 P28715 1/20 0.41
FEN1 P39748 1/20 0.41
ERCC4 Q92889 1/20 0.41
ALDH1A1 P00352 1/20 0.41
KMT2A Q03164 1/20 0.40
PDE7A Q13946 4/20 0.40
ADORA1 P30542 2/20 0.39
MAPK8 P45983 1/20 0.39
PARG Q86W56 1/20 0.37
POLB P06746 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
PDE7B Q9NP56 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6522410 0.81 ALDH1A1 (0.50) ADORA2BADORA2APDE4BPDE4APDE4C
SCHEMBL6514929 0.80 ADORA2B (0.40) ADORA2BERCC1ERCC5FEN1ERCC4
SCHEMBL6513423 0.80 ERCC1 (0.63) ADORA2BERCC1ERCC5FEN1ERCC4
SCHEMBL7015507 0.78 ADORA2B (0.39) ADORA2BERCC1ERCC5FEN1ERCC4
SCHEMBL7015510 0.78 ADORA2B (0.39) ADORA2BERCC1ERCC5FEN1ERCC4
SCHEMBL7017008 0.77 ADORA2B (0.38) ADORA2BERCC1ERCC5FEN1ERCC4
SCHEMBL7017712 0.77 ADORA2B (0.40) ADORA2BERCC1ERCC5FEN1ERCC4
SCHEMBL7017710 0.77 ADORA2B (0.40) ADORA2BERCC1ERCC5FEN1ERCC4
SCHEMBL7017005 0.77 ADORA2B (0.38) ADORA2BERCC1ERCC5FEN1ERCC4
SCHEMBL7101330 0.76 ADORA2B (0.40) ADORA2BERCC1ERCC5FEN1ERCC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004126-A1 Method of determining potential allosterically-binding matrix metalloproteinase inhibitors ANDRIANJARA CHARLES (FR) 2005-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004126-A1 Method of determining potential allosterically-binding matrix metalloproteinase inhibitors MMP13, MMP12, MMP25 ADORA2B 3585/4885ADORA2A 2900/4885PDE4B 3058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.